Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Stoke Therapeutics
Biotech
Stoke aims to restore developmental loss in Dravet syndrome
Stoke CEO Ian Smith said the company is seeing seizure reductions of up to 85% on top of standard-of-care medicines.
Gabrielle Masson
Mar 18, 2026 2:57pm
Former CBER chief Peter Marks leaps to Lilly—Chutes & Ladders
Oct 10, 2025 8:30am
Former FDA deputy joins AI biotech's board—Chutes & Ladders
Mar 21, 2025 8:30am
Biogen pays Stoke $165M, bagging Dravet drug to fire up pipeline
Feb 18, 2025 9:28am
BMS vet answers Foghorn’s call for CBO—Chutes & Ladders
Sep 6, 2024 8:30am
Stoke's Dravet syndrome med released of partial clinical hold
Aug 7, 2024 8:54am
